New Drug-Free Quit Smoking Lozenge Maker Announces Distribution Approval in Some European Countries [09/24/04]

New Drug-Free Quit Smoking Lozenge Maker Announces Distribution Approval in Some European Countries [09/24-5]

Excerpts from: Nicodrops Announces European Community 'EC' Approval; Assures Global Presence by Q-1 of 2005

Business Wire [09/23/04]

(NCDP) today announced that it has formally received approval from the European Community (EC) to allow the company to distribute its proprietary products in the following 15 countries; UK, Ireland, Spain, Portugal, France, Germany, Italy, Greece, Belgium, Norway, Sweden, Denmark, Finland, Switzerland, and the Netherlands.

Nicodrops has now moved into the international marketplace to aggressively capture a significant share of the $2.5 Billion global market for smoking cessation products with the first non-nicotine, drug-free product with no known side effects.

Nicodrops will be manufactured and packaged in the UK or the Netherlands under licensing arrangements with Nicodrops, Inc. These manufacturing facilities will produce the finished lozenges from proprietary raw materials provided by the Company.

"We are quite pleased to add the EC market to the retail distribution being assembled in the US and Canadian markets" said Mr. Christopher Calpito, President and Chief Executive Officer of Nicodrops. "This addition of a Mega-Market like the EC" continued Mr. Calpito "brings us that much closer to our Threshold Corporate Objective ("TCO") of gaining a visible market share of the global market for smoking cessation products."

Nicodrops, Inc. was incorporated for the purpose of bringing to market a unique, drug free line of lozenge products designed to help people who wish to stop smoking. The Company has developed its smoking cessation product over a ten-year period. With the completion of the product development, Nicodrops is now positioned to capitalize on the research and development activities by introducing their products to the market place.

Unlike its competitors, the product is drug free, acts faster and is less expensive. The product also assists those who wish to stop smoking without using the nicotine weaning process included in competing products. Introducing the drug-based products into the blood stream only heightens the risk of a heart attack if a person decides go back to smoking again. Nicodrops is a much safer and better product because it is drug-free and requires a much shorter time to show tangible results (less than 4 weeks compared to the drug based products that are 12 weeks or longer. Nicodrops lozenge is a no non-sense straightforward approach to begin a stop smoking program without using nicotine right from the onset. It will also assist smokers who cannot smoke during business hours. Nicodrops is a smoker's best ally in a smoker-unfriendly environment. It just might convert a smoker - somewhat inadvertently perhaps - into a non-smoker.

Presented as a public service by Action on Smoking and Health (ASH),
2013 H Street, N.W., Wash., DC 20006, USA, (202) 659-4310.
ASH is a 36-year-old national legal-action antismoking and nonsmokers' rights organization which is entirely supported by tax-deductible contributions.
Please credit ASH, and include ASH's web address: http://ash.org

Raising Smoking in a Custody Dispute	Smoking in Condos and Apartments	File Complaints Against Smoking	Toxins in Tobacco Smoke	Dangers of Secondhand Smoke	Govt. Rpt. on Secondhand Smoke
Tobacco Class-Action Law Suits	Sue-Big-Tobacco List of Lawyers	Tobacco Settlement, Multistate	ASH's New International Site	Smoking Facts & Statistics	Children and Smoking